Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application

04/08/2021 | 05:43am EDT

By Matt Grossman

Bristol Myers Squibb Co. said Thursday that a Phase 3 trial testing the use of its Opdivo and Yervoy medications to treat unresectable advanced or metastatic esophageal squamous cell carcinoma showed positive results.

The trial tested the efficacy of two treatments: Opdivo plus chemotherapy, and Opdivo plus Yervoy.

Opdivo plus chemotherapy met its primary and secondary endpoints of providing a benefit both to patients whose tumors express PD-L1, and in the all-randomized population. The combination also met its primary endpoint of progression-free survival by blinded independent central review in patients whose tumors express PD-L1.

Opdivo plus Yervoy also demonstrated improvement in overall survival in patients whose tumors express PD-L1 and in the all-randomized population. It didn't meet the other primary endpoint of progression-free survival by BICR in patients whose tumors express PD-L1.

The drugs' safety profiles were consistent with prior research, the company said.

Dr. Ian Waxman, Bristol Myers Squibb's development lead for gastrointestinal cancers, said the results could lead to new treatment options for patients with esophageal cancer.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

04-08-21 0743ET

All news about BRISTOL-MYERS SQUIBB COMPANY
06:28aBRISTOL MYERS SQUIBB  : Opdivo Meets Phase 3 Lung Cancer Study Goals
MT
04/10BRISTOL MYERS SQUIBB  : Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Signifi..
BU
04/08BRISTOL MYERS SQUIBB  : Dual Therapies Beat Chemotherapy in Phase 3 Trial
MT
04/08BRISTOL MYERS SQUIBB  :  CORRECTING and REPLACING Bristol Myers Squibb Announces..
BU
04/08Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Addit..
DJ
04/07BRISTOL MYERS SQUIBB  : PsiOxus to Advance Cancer Therapy Assessment
MT
04/01IPSEN S A  : European Commission approves Cabometyx in combination with Opdivo a..
AQ
04/01AGIOS PHARMACEUTICALS  : Closes Oncology Business Sale to Servier
MT
03/31BRISTOL MYERS SQUIBB  : Ono Pharmaceutical Co., Ltd - European Medicines Agency ..
AQ
03/31EXELIXIS  : Says Partner Ipsen Gets Regulatory Nod for Use of Cabometyx With Opd..
MT
More news
Financials (USD)
Sales 2021 46 236 M - -
Net income 2021 7 636 M - -
Net Debt 2021 31 085 M - -
P/E ratio 2021 18,8x
Yield 2021 3,13%
Capitalization 140 B 140 B -
EV / Sales 2021 3,70x
EV / Sales 2022 3,31x
Nbr of Employees 30 250
Free-Float 76,2%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 75,18 $
Last Close Price 62,61 $
Spread / Highest target 37,4%
Spread / Average Target 20,1%
Spread / Lowest Target 5,41%
EPS Revisions
Managers and Directors
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY0.94%139 866
JOHNSON & JOHNSON2.46%424 524
ROCHE HOLDING AG0.21%288 043
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164